EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis

A Pinter iD, A Reich, P Arenberger iD, L S Gold iD, A Armstrong, L Iversen, M Praestegaard, M Augustin iD

Journal of the European Academy of Dermatology and Venereology · 2023

DOI: 10.1111/jdv.19330 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von A Pinter und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: Psoriasis, Dermatologic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: MC2 Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The fixed dose combination of calcipotriene (CAL) and betamethasone dipropionate (BDP) is a well‐established topical treatment option for psoriasis based on strong scientific rationale for the single agents having complementary efficacy and safety. CAL/BDP PAD‐cream is an easily spreadable cream based on PAD Technology™, an innovative formulation and drug delivery system. Objectives and Methods A Phase 3, multicentre, randomized, investigator‐blind, active and vehicle‐controlled trial enrolling 490 patients with mild to moderate psoriasis according to the Physician Global Assessment (PGA) scale was conducted in three European countries. Products were applied once daily for 8 weeks. The aim of the trial was to evaluate the efficacy and safety of CAL/BDP PAD‐cream as well as treatment acceptability compared to CAL/BDP gel and PAD‐cream vehicle. Primary endpoint was percentage change in modified Psoriasis Area and Severity Index (mPASI) from baseline to Week 8.

Results

The percentage mean change from baseline to Week 8 in mPASI for CAL/BDP PAD‐cream (67.5%) was superior compared to PAD‐cream vehicle (11.7%; p < 0.0001) and non‐inferior to CAL/BDP gel (63.5%). The proportion of patients achieving PGA treatment success (at least two‐step improvement to clear or almost clear) after 8 weeks was superior for CAL/BDP PAD‐cream (50.7%) compared to PAD‐cream vehicle (6.1%, p < 0.0001) and statistically significantly greater than CAL/BDP gel (42.7%, p = 0.0442). Patient‐reported psoriasis treatment convenience score (PTCS) for CAL/BDP PAD‐cream was rated superior to CAL/BDP gel at Week 8 ( p < 0.0001) and the mean change in DLQI from baseline to Week 8 improved statistically significantly more in the CAL/BDP PAD‐cream group compared to both PAD‐cream vehicle ( p < 0.0001) and CAL/BDP gel ( p = 0.0110). Safety assessments during the trial demonstrated that CAL/BDP PAD‐cream was well‐tolerated.

Conclusion

CAL/BDP PAD‐cream is a novel topical treatment of psoriasis that has a high efficacy and a favourable safety profile combined with a superior patient‐reported treatment convenience.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisDermatologic AgentsHumansDrug CombinationsCalcitriolBetamethasoneTreatment OutcomeEmollients

Substanzen

calcipotrienebetamethasone-17,21-dipropionateDrug CombinationsCalcitriolBetamethasoneEmollientsDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany.
  • Department of Dermatology, University of Rzeszow, Rzeszów, Poland.
  • Charles University, Prague, Czech Republic.
  • Dermatology Clinical Research, Henry Ford Health System, Detroit, Michigan, USA.
  • University of Southern California, Los Angeles, California, USA.
  • MC2 Therapeutics, Hørsholm, Denmark.

ORCID-Profile: A Pinter, P Arenberger, L S Gold, M Augustin

Förderung

  • MC2 Therapeutics

Zitieren

APA

Pinter, A., Reich, A., Arenberger, P., Gold, L. S., Armstrong, A., Iversen, L., Praestegaard, M., & Augustin, M. (2023). Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19330

Vancouver

Pinter A, Reich A, Arenberger P, Gold LS, Armstrong A, Iversen L, et al. Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19330

BibTeX
@article{Pinter2023,
  author = {Pinter, A and Reich, A and Arenberger, P and Gold, L S and Armstrong, A and Iversen, L and Praestegaard, M and Augustin, M},
  title = {Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  doi = {10.1111/jdv.19330}
}
Kostenlos starten →